SCHEMBL4975762

SCHEMBL4975762

CN(C)C(O[C]=O)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HTR2A P28223 4/20 0.38
HRH1 P35367 4/20 0.38
TDP1 Q9NUW8 1/20 0.36
LMNA P02545 3/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRM1 P11229 2/20 0.35
CYP1A2 P05177 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
ADRA2A P08913 1/20 0.35
CYP2D6 P10635 1/20 0.35
TSHR P16473 1/20 0.35
ADRA2B P18089 1/20 0.35
CHRM3 P20309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4538293 0.76 KDM4E (0.45) KDM4EALDH1A1HTR2AHRH1TDP1
SCHEMBL27539875 0.74 KDM4E (0.43) KDM4EALDH1A1HTR2AHRH1TDP1
SCHEMBL119992 0.72 TSHR (0.44) ALDH1A1LMNACYP1A2CYP2D6TSHR
SCHEMBL96935 0.72 HCAR2 (0.43) KDM4EALDH1A1LMNAADRA2AADRA2B
SCHEMBL16970628 0.72 HCAR2 (0.43) KDM4EALDH1A1LMNAADRA2AADRA2B
SCHEMBL7454768 0.72 TSHR (0.44) ALDH1A1LMNACYP1A2CYP2D6TSHR
SCHEMBL16970750 0.72 HCAR2 (0.43) KDM4EALDH1A1LMNAADRA2AADRA2B
SCHEMBL857 0.72 IDO1 (0.39) HTR2AHRH1LMNACHRM1CYP1A2
SCHEMBL9793557 0.71 KMT2A (0.46) KDM4EALDH1A1CHRNB2CHRNB4CHRNA3
SCHEMBL5519744 0.69 THRB (0.42) KDM4EALDH1A1HTR2ALMNACHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080033165-A1 [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use KOPPEL GARY A 2008-02-07 US disclosed
US-7268125-B2 β-lactamyl vasopressin V1a antagonists AZEVAN PHARMACEUTICALS, INC. (US) 2007-09-11 US disclosed
US-20060217364-A1 Beta-lactamyl vasopressin V1a antagonists NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217364-A1 Beta-lactamyl vasopressin V1a antagonists AVPR1A, AVPR2, AVPR1B KDM4E 3653/4885ALDH1A1 1170/4885HTR2A 170/4885
US-20080033165-A1 [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use AVPR2, AVPR1A, AVPR1B KDM4E 2755/4885ALDH1A1 818/4885HTR2A 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.